<Record>
<Term>Eculizumab</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<SemanticType>Organic Chemical</SemanticType>
<ParentTerm>Monoclonal Antibody</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Biological Agent/Monoclonal Antibody/Eculizumab</ClassificationPath>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Eculizumab</BroaderTerm>
<BroaderTerm>Biological Agent</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Monoclonal Antibody</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>h5G1.1</Synonym>
<Synonym>Eculizumab</Synonym>
<Synonym>Monoclonal antibody 5G1.1</Synonym>
<Synonym>Alexion</Synonym>
<Synonym>Soliris</Synonym>
<Synonym>ECULIZUMAB</Synonym>
<Description>A human monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)</Description>
<Source>FDA Registry</Source>
<Source>NCI Thesaurus</Source>
</Record>
